Pfizer Inc vs Vital Farms Inc — how do they compare? Pfizer Inc trades at $24.91 (market cap $142.14B), while Vital Farms Inc trades at $13.03 (market cap $561.74M). The key difference: Pfizer Inc is far larger — about 253× Vital Farms Inc's market cap, and Pfizer Inc pays a 6.9% dividend while Vital Farms Inc pays none. Which is the better fit depends on your goals.
| PFE | VITL | |
|---|---|---|
Market Cap | $142.14B | $561.74M |
Volume | 29,869,932 | — |
Sector | Health | Consumer Staples |
52-Week High | $28.56 | $52.41 |
52-Week Low | $23.29 | $8.28 |
Enterprise Value | $192.80B | $564.55M |
Dividend Yield | 6.9% | — |
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.
Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.
Vital Farms (VITL) trades at $13.76, up 1.55% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 15.44% ROE and trades at a modest P/E of 13.25. Recent earnings have been mixed, with a Q3 2025 beat but Q1 2026 miss, while analyst sentiment remains positive with 56% buy ratings. Net cash flow is negative due to significant investing activities, and a class action lawsuit filed in May 2026 adds legal overhang.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but near-term performance hinges on reversing negative earnings surprises and managing legal risks. The consensus price target of $13.50 suggests limited upside from current levels, with execution on revenue growth and margin stabilization key to driving shareholder value.
Trailing returns across standard periods
Latest headlines on both assets
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →